Aug. 11 at 9:25 AM
$ABCL I think a sleeper catalyst is the announcement of ABCL688’s target, which Phase 1 is planned for 2027
It’s another program that can target GPCR or Ion channels, information is not given yet as what specific target, all we know it’s an autoimmune-disease program
I will be very curious to know what it is, perhaps it’s something even larger in terms of valuation compared to ABCL635
If it’s another validated GPCR with a even larger market, well god help anyone trying to short this in the future
I am assuming we will hear news soon, market not giving these programs their flowers properly